{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T10:01:55Z","timestamp":1768557715360,"version":"3.49.0"},"reference-count":20,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,1,15]],"date-time":"2024-01-15T00:00:00Z","timestamp":1705276800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004326","name":"Bayer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004326","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Heart Journal"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1016\/j.ahj.2024.01.001","type":"journal-article","created":{"date-parts":[[2024,1,11]],"date-time":"2024-01-11T22:50:21Z","timestamp":1705013421000},"page":"191-200","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["Identifying the highest risk vascular patients: Insights from the XATOA registry"],"prefix":"10.1016","volume":"269","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3692-7441","authenticated-orcid":false,"given":"Sonia S.","family":"Anand","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Victor","family":"Aboyans","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jackie","family":"Bosch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sebastian","family":"Debus","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alain","family":"Gay","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manesh R.","family":"Patel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kai","family":"Vogtl\u00e4nder","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert C.","family":"Welsh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Uwe","family":"Zeymer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keith A.A.","family":"Fox","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.ahj.2024.01.001_bib0001","first-page":"e1","article-title":"Highlighting residual atherosclerotic cardiovascular disease risk","volume":"39","author":"Yunosuke","year":"2019","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"4","key":"10.1016\/j.ahj.2024.01.001_bib0002","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1161\/CIRCULATIONAHA.117.032235","article-title":"Low-density lipoprotein cholesterol lowering with evolocumab and outcomes in patients with peripheral artery disease: insights from the FOURIER Trial (further cardiovascular outcomes research with PCSK9 inhibition in subjects with elevated risk)","volume":"137","author":"Bonaca","year":"2018","journal-title":"Circulation"},{"issue":"11","key":"10.1016\/j.ahj.2024.01.001_bib0003","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1016\/j.jacc.2017.07.768","article-title":"Efficacy and safety of ticagrelor over time in patients with prior MI in PEGASUS-TIMI 54","volume":"70","author":"Bonaca","year":"2017","journal-title":"J Am Coll Cardiol"},{"issue":"5","key":"10.1016\/j.ahj.2024.01.001_bib0004","first-page":"560","article-title":"Canadian Cardiovascular Society 2022 guidelines for peripheral arterial disease","volume":"38","author":"Primary","year":"2022","journal-title":"Can J Cardiol"},{"issue":"5","key":"10.1016\/j.ahj.2024.01.001_bib0005","first-page":"553","article-title":"Peripheral artery disease: a high-risk yet understudied, underdiagnosed, and undertreated condition\u2014a call to action","volume":"38","author":"Mastracci","year":"2022","journal-title":"Can J Cardiol"},{"issue":"5","key":"10.1016\/j.ahj.2024.01.001_bib0006","first-page":"634","article-title":"Building your peripheral artery disease toolkit: medical management of peripheral artery disease in 2022","volume":"38","author":"Bhagirath","year":"2022","journal-title":"Can J Cardiol"},{"issue":"14","key":"10.1016\/j.ahj.2024.01.001_bib0007","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1056\/NEJMoa1709118","article-title":"Rivaroxaban with or without aspirin in stable cardiovascular disease","volume":"377","author":"Eikelboom","year":"2017","journal-title":"N Engl J Med"},{"issue":"21","key":"10.1016\/j.ahj.2024.01.001_bib0008","doi-asserted-by":"crossref","first-page":"1994","DOI":"10.1056\/NEJMoa2000052","article-title":"Rivaroxaban in peripheral artery disease after revascularization","volume":"382","author":"Bonaca","year":"2020","journal-title":"N Engl J Med"},{"issue":"25","key":"10.1016\/j.ahj.2024.01.001_bib0009","doi-asserted-by":"crossref","first-page":"3271","DOI":"10.1016\/j.jacc.2019.02.079","article-title":"Rivaroxaban plus aspirin versus aspirin in relation to vascular risk in the COMPASS trial","volume":"73","author":"Anand","year":"2019","journal-title":"J Am Coll Cardiol"},{"issue":"8","key":"10.1016\/j.ahj.2024.01.001_bib0010","first-page":"825","article-title":"Patients selected for dual pathway inhibition in clinical practice have similar characteristics and outcomes to those included in the COMPASS randomized trial: the XATOA Registry","volume":"8","author":"Fox","year":"2022","journal-title":"Eur Heart J"},{"issue":"3","key":"10.1016\/j.ahj.2024.01.001_bib0011","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1198\/106186006X133933","article-title":"Unbiased recursive partitioning: a conditional inference framework","volume":"15","author":"Hothorn","year":"2006","journal-title":"J Comput Graph Stat"},{"issue":"3","key":"10.1016\/j.ahj.2024.01.001_bib0012","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1207\/S15324796ABM2603_02","article-title":"Classification and regression tree analysis in public health: Methodological review and comparison with logistic regression","volume":"26","author":"Lemon","year":"2003","journal-title":"Ann Behav Med"},{"key":"10.1016\/j.ahj.2024.01.001_bib0013","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.atherosclerosis.2020.11.001","article-title":"Polyvascular disease: a narrative review of current evidence and a consideration of the role of antithrombotic therapy","volume":"315","author":"Weissler","year":"2020","journal-title":"Atherosclerosis"},{"issue":"4","key":"10.1016\/j.ahj.2024.01.001_bib0014","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1177\/1358863X10373299","article-title":"Influence of polyvascular disease on cardiovascular event rates. Insights from the REACH Registry","volume":"15","author":"Su\u00e1rez","year":"2010","journal-title":"Vasc Med"},{"issue":"4","key":"10.1016\/j.ahj.2024.01.001_bib0015","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1161\/CIRCULATIONAHA.117.032235","article-title":"Low-density lipoprotein cholesterol lowering with evolocumab and outcomes in patients with peripheral artery disease","volume":"137","author":"Marc","year":"2018","journal-title":"Circulation"},{"issue":"7","key":"10.1016\/j.ahj.2024.01.001_bib0016","doi-asserted-by":"crossref","first-page":"e185239","DOI":"10.1001\/jamanetworkopen.2018.5239","article-title":"Polyvascular disease and risk of major adverse cardiovascular events in peripheral artery disease: a secondary analysis of the EUCLID trial","volume":"1","author":"Gutierrez","year":"2018","journal-title":"JAMA Netw Open"},{"issue":"2","key":"10.1016\/j.ahj.2024.01.001_bib0017","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.pcad.2015.07.003","article-title":"Oral anticoagulant therapy in atrial fibrillation patients at high stroke and bleeding risk","volume":"58","author":"Potpara","year":"2015","journal-title":"Prog Cardiovasc Dis"},{"issue":"1","key":"10.1016\/j.ahj.2024.01.001_bib0018","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa1112277","article-title":"Rivaroxaban in patients with a recent acute coronary syndrome","volume":"366","author":"Mega","year":"2011","journal-title":"N Engl J Med"},{"issue":"25","key":"10.1016\/j.ahj.2024.01.001_bib0019","doi-asserted-by":"crossref","first-page":"3274","DOI":"10.1016\/j.jacc.2018.09.078","article-title":"Cardiovascular and limb outcomes in patients with diabetes and peripheral artery disease","volume":"72","author":"Cecilia","year":"2018","journal-title":"J Am Coll Cardiol"},{"issue":"6","key":"10.1016\/j.ahj.2024.01.001_bib0020","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1161\/CIRCULATIONAHA.119.040672","article-title":"Microvascular disease, peripheral artery disease, and amputation","volume":"140","author":"Joshua","year":"2019","journal-title":"Circulation"}],"container-title":["American Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002870324000012?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002870324000012?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T06:12:43Z","timestamp":1757571163000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002870324000012"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3]]},"references-count":20,"alternative-id":["S0002870324000012"],"URL":"https:\/\/doi.org\/10.1016\/j.ahj.2024.01.001","relation":{},"ISSN":["0002-8703"],"issn-type":[{"value":"0002-8703","type":"print"}],"subject":[],"published":{"date-parts":[[2024,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Identifying the highest risk vascular patients: Insights from the XATOA registry","name":"articletitle","label":"Article Title"},{"value":"American Heart Journal","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ahj.2024.01.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}